Click on a filter below to refine your search. Remove a filter to broaden your search.
The authors highlight that the volume of hospitalizations for COVID-19 was double that of the volume for flu.
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
Care models are informed by five key principles, including multidisciplinary expertise and a patient-centered approach.
Differences were identified in circulating myeloid and lymphocyte populations, as well as exaggerated humoral responses against SARS-CoV-2.
The findings compared with placebo at 28-day and 43-day follow-up.
Odds ratio of 6.30 for Guillain-Barré syndrome association with SARS-CoV-2 infection and 0.41 for COVID-19 vaccine administration.
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
SARS-CoV-2 targets plaque macrophages, and its entry is increased in cholesterol-loaded primary macrophages.
A fourth dose reduces the risk for SARS-CoV-2 for patients with systemic autoimmune rheumatic diseases using DMARDs.
Researchers find increased prevalence/severity of most symptoms and reduced health-related quality of life.